Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes (Q35140086)

6 August 2017

1 reference

title

Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes (English)

1 reference

6 August 2017

0 references

Baihua Hu

1

1 reference

6 August 2017

Lee L Jennings

series ordinal

2

1 reference

6 August 2017

publication date

1 January 2003

1 reference

Progress in medicinal chemistry

6 August 2017

published in

1 reference

6 August 2017

volume

41

1 reference

6 August 2017

page(s)

167-194

1 reference

Annual Deaths Attributable to Obesity in the United States

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Obesity as a medical problem

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Anti-obesity drugs: a critical review of current therapies and future opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Pharmacological treatment of obesity: therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Beta3-adrenergic agonists: potential therapeutics for obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Structure and function of the beta 3-adrenergic receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Distribution of beta 3-adrenoceptor mRNA in human tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Molecular characterization of the human beta 3-adrenergic receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Meta-analysis of the association of Trp64Arg polymorphism of beta 3-adrenergic receptor gene with body mass index

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Relationship of the Trp64Arg polymorphism of the beta3-adrenoceptor gene to central adiposity and high blood pressure: interaction with age. Cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Cloning of the cDNA for the human beta 1-adrenergic receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Expression of three human beta-adrenergic-receptor subtypes in transfected Chinese hamster ovary cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Targeted disruption of the beta 3-adrenergic receptor gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Towards a molecular understanding of adaptive thermogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Beta 3-adrenergic agonist up-regulates uncoupling proteins 2 and 3 in skeletal muscle of the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Uncoupling proteins: their roles in adaptive thermogenesis and substrate metabolism reconsidered

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Up-regulation of uncoupling proteins by beta-adrenergic stimulation in L6 myotubes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Time of Onset of Non-Insulin-Dependent Diabetes Mellitus and Genetic Variation in the β3-Adrenergic–Receptor Gene

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Prodrugs of CL316243: a selective beta3-adrenergic receptor agonist for treating obesity and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Novel (4-piperidin-1-yl)-phenyl sulfonamides as potent and selective human beta(3) agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

New oxadiazolidinedione derivatives as potent and selective human beta3 agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

(4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

2,4-Thiazolidinediones as potent and selective human beta3 agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

4-Aminopiperidine ureas as potent selective agonists of the human beta(3)-adrenergic receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Human beta3 adrenergic receptor agonists containing cyanoguanidine and nitroethylenediamine moieties

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Tetrahydroisoquinoline derivatives containing a benzenesulfonamide moiety as potent, selective human beta3 adrenergic receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Potent, elective human beta3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

L-770,644: a potent and selective human beta3 adrenergic receptor agonist with improved oral bioavailability.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

3-Pyridyloxypropanolamine agonists of the beta 3 adrenergic receptor with improved pharmacokinetic properties

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Discovery of L-755,507: a subnanomolar human beta 3 adrenergic receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Potent, selective benzenesulfonamide agonists of the human beta 3 adrenergic receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Beta 3 agonists. Part 1: evolution from inception to BMS-194449.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Mechanism of amelioration of insulin resistance by beta3-adrenoceptor agonist AJ-9677 in the KK-Ay/Ta diabetic obese mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Sustained improvement in glucose homeostasis in lean and obese mice following chronic administration of the beta 3 agonist SR 58611A.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence: 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Up-regulation of muscle UCP2 gene expression by a new β3-adrenoceptor agonist, trecadrine, in obese (cafeteria) rodents, but down-regulation in lean animals

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Effects of the oral administration of a beta3-adrenergic agonist on lipid metabolism in alloxan-diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Potential anti-diabetic applications of a new molecule with affinity for beta 3-adrenoceptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

Aryl propanolamines: comparison of activity at human beta3 receptors, rat beta3 receptors and rat atrial receptors mediating tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

L-750355, a human beta3-adrenoceptor agonist; in vitro pharmacology and profile of activity in vivo in the rhesus monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2802%2941005-3

7 January 2021

10.1016/S0079-6468(02)41005-3

Identifiers

DOI

1 reference

6 August 2017

1 reference